ALSO NOTED: China accuses U.S. of obstructing heparin probe; GSK exec charges Mass. with demonizing pharma;

> China continues to point fingers at the U.S. over the heparin investigation, saying the FDA refused to hand over details about patients who experienced severe allergic reactions to the blood thinner. Report | Report

> GlaxoSmithKline's top U.S. exec, Christopher Viehbacher, harshly criticized Massachusetts' plans to bar drugmakers' gifts to doctors in letters sent to state Senate President Therese Murray, House Speaker Sal DiMasi, and Gov. Deval Patrick. Report

> Discount retailer Target is matching Wal-Mart's recent expansion of its cheap generics program. Report

> Par Pharmaceutical bought Spectrum's interest in the generic versions of GlaxoSmithKline's migraine drug Imitrex, boosting its share of profits to 95 percent from 38 percent once the products are launched late this year or early next. Release

> Lundbeck posted a 40 percent increase in first-quarter profits on a 12 percent growth in revenues, beating market estimates. Report

> OSI Pharmaceuticals saw its first-quarter earnings jump to $29.2 million, or 49 cents per share, from 12 cents per share last year on higher sales of its cancer med Tarceva. Report

> Onyx Pharmaceuticals reported a street-beating first-quarter profit of $15.4 million on fast-growing sales of its cancer med Nexavar. Report

> MAP Pharmaceuticals announced that it secured a $20 million loan for working capital from Oxford Finance and Silicon valley Bank. Release

> Pharma wholesaler McKesson has agreed to pay $13 million in fines for failing to report large and frequent Internet sales of controlled substances. Report

> Shares of France's NicOx tumbled 38 percent after Pfizer announced that it would not advance their experimental therapy for glaucoma into Phase III. NicOx report

> One analyst is predicting a long delay for Merck's Cordaptive. Report

> Two doctors engaged in RNA research became the first women to win the prestigious Albany Medical Center Prize, one of the richest awards available for biomedical research. Report

> Researchers for Purdue Pharma laid out their data for a new, tamper-resistant form of the blockbuster OxyContin to an expert FDA panel, and promptly had their heads handed back to them. Report

And Finally... UK cell biologist Robert Edwards says he can see a time in the not-too-distant future when humans will be able to grow new body parts through the use of stem cell technology. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.